HISUN(SH:600267) Jing Ji Guan Cha Wang·2026-01-18 04:31Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has been issued warning letters due to inaccurate financial information, affecting its two former chairmen and several executives [1][2]. Group 1: Regulatory Actions - The China Securities Regulatory Commission (CSRC) Zhejiang Bureau issued warning letters to the company and its executives for violations of the Information Disclosure Management Measures [2]. - The company and its executives, including former chairmen Jiang Guoping and Shen Xinghu, are now recorded in the integrity archives of the securities and futures market [2]. Group 2: Financial Corrections - The company announced corrections to its financial data for the years 2021-2024, which included adjustments to operating income, operating costs, and investment income [1][4]. - The total adjustments included a reduction of operating income by 948.83 million yuan and a reduction of operating costs by 930.03 million yuan for the years 2021-2023 [4]. Group 3: Company Background - Zhejiang Haizheng Pharmaceutical is a state-owned enterprise based in Taizhou, Zhejiang, with a diverse portfolio in chemical, biological, animal, and traditional Chinese medicine [2]. - The company has been involved in financial discrepancies for four consecutive years, linked to its subsidiary Zhejiang Pharmaceutical Co., Ltd. [3]. Group 4: Business Restructuring - In December 2025, the company announced the sale of its subsidiary Zhejiang Pharmaceutical to optimize its business structure and focus on core pharmaceutical areas [4]. - The sale was confirmed with Guangzhou Pharmaceutical Co., Ltd. for a transaction price of 505 million yuan [4].